New targeted drugs for advanced lung cancer with EGFR L858R
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old and willing to sign informed consent
- Have advanced non-small cell lung cancer that cannot be removed by surgery (stage IIIB/IV), confirmed by tissue testing
- Your cancer should have the EGFR mutation: Phase I allows exon 21 L858R or exon 19 deletion, while Phase IIb requires exon 21 L858R only
- Have at least one tumor spot that can be measured on scans, and have stable or controlled brain metastases
- Have not had any prior drug treatment for advanced lung cancer, and be able to take oral medicines
- Have generally healthy blood, liver, kidney, and heart function, and be well enough to do daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.